Email
IZ Express #1,621: Immunize.org updates pneumococcal and zoster standing order templates and more
| From | Immunization Action Coalition <[email protected]> |
| Subject | IZ Express #1,621: Immunize.org updates pneumococcal and zoster standing order templates and more |
| Date | March 16, 2022 10:00 AM |
Links have been removed from this email. Learn more in the FAQ.
Links have been removed from this email. Learn more in the FAQ.
[link removed]
[link removed]
[link removed]
[link removed] [link removed]
Email not displaying correctly? View it in your browser ([link removed]).
[link removed]
Issue 1,621: March 16, 2022 Formerly IAC Express
Top Stories
* Immunize.org updates two of its popular standing order templates with new CDC recommendations: pneumococcal vaccination of adults and zoster (shingles) vaccination
* "Ask the Experts: Zoster" web page updated with new clinical considerations for vaccination of immunocompromised adults age 19 and older
* Immunize.org posts new Vaccine Information Statements (VISs) in eight languages for pneumococcal conjugate vaccine (PCV) and recombinant zoster vaccine
* Order today! Laminated versions of CDC’s 2022 immunization schedules will begin to ship this week.
* “Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection among Children Aged 5–11 Years and Adolescents Aged 12–15 Years—PROTECT Cohort, July 2021–February 2022” published in MMWR
* CDC updates PneumoRecs VaxAdvisor mobile app for vaccine providers
* Unity Consortium launches Adolescent Immunization Action Week, April 4–8, with release of partner toolkit
* Influenza season is not done yet; activity low but increased slightly in most of the country. Keep offering to vaccinate.
* HHS seeks stakeholder comments on its draft Vaccines Federal Implementation Plan 2021–2025; deadline March 29
* Spotlight! Immunize.org's "Clinic Tools” main page is a one-stop source of practical information for vaccination providers
* Journalists interview Immunize.org experts
* Vaccines in the news
Immunize.org Pages and Handouts
* New! Keep up to date using Immunize.org’s new “Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools” and updated COVID-19 main page.
* "Ask the Experts: COVID-19" web page updated with newest CDC clinical considerations, including expanded dose intervals for mRNA vaccines
* Visit Immunize.org's “Vaccines: COVID-19” main page to locate the latest information on COVID-19 vaccines
Featured Resources
* 65+ Flu Defense website offers resources for healthcare professionals serving older adults
* Use Immunize.org's Vaccinating Adults: A Step-by-Step Guide—free to download by chapter or in its entirety.
Notable Publications
* “Interim Estimates of 2021–22 Seasonal Influenza Vaccine Effectiveness—United States, February 2022” published in MMWR
* “COVID-19 Vaccine Provider Access and Vaccination Coverage among Children Aged 5–11 Years—United States, November 2021–January 2022” published in MMWR
* MMWR Recap: Articles regarding COVID-19 vaccine effectiveness and safety monitoring
Global News
* WHO confirms circulating vaccine-derived poliovirus in Israel
Upcoming Events
* Virtual: NFID hosts "Updates from Recent Advisory Committee on Immunization Practices (ACIP) Meetings" webinar on March 17
* Virtual and In Person: Registration open for "North Dakota Immunization Conference" on June 21–22; CE available
------------------------------------------------------------
Top Stories
------------------------------------------------------------
Immunize.org updates two of its popular standing order templates with new CDC recommendations: pneumococcal vaccination of adults and zoster (shingles) vaccination
Immunize.org recently revised its Standing Orders for Administering Pneumococcal Vaccines (PCV15, PCV20, and PPSV23) to Adults ([link removed]) and Standing Orders for Administering Recombinant Zoster Vaccine to Adults ([link removed]) templates.
The Standing Orders for Administering Pneumococcal Vaccines (PCV15, PCV20, and PPSV23) to Adults ([link removed]) template incorporates the new CDC recommendations published in January 2022. This template covers the use of 15-valent pneumococcal conjugate vaccine (PCV15, Vaxneuvance, Merck), PCV20 (Prevnar20, Pfizer), and 23-valent pneumococcal polysaccharide vaccine (PPSV23, Pneumovax 23, Merck). The document outlines what to do for previously unvaccinated adults, as well as adults with a history of vaccination with PCV13 and/or PPSV23.
The Standing Orders for Administering Recombinant Zoster Vaccine to Adults ([link removed]) template was updated with information on the new CDC recommendations for use of recombinant zoster vaccine (RZV, Shingrix, GSK) in adults age 19 and older who are or will be immunodeficient or immunosuppressed as a result of disease or therapy. For patients in this category, the standing orders recommend consultation with the medical director and—as needed—the provider primarily responsible for managing the patient’s immunocompromising condition or therapy. This is because the complex and highly variable nature of immunocompromising conditions may affect the optimal timing of vaccination.
Related Links
* Immunize.org: Standing Orders for Administering Pneumococcal Vaccines (PCV15, PCV20, and PPSV23) to Adults ([link removed])
* Immunize.org: Standing Orders for Administering Recombinant Zoster Vaccine to Adults ([link removed])
* Immunize.org: Using Standing Orders for Administering Vaccines: What You Should Know ([link removed])
* Immunize.org: 10 Steps to Implementing Standing Orders for Immunization in Your Practice Setting ([link removed])
* Immunize.org: Standing Orders Templates for Administering Vaccines ([link removed]) web page
* Immunize.org: Ask the Experts: Zoster ([link removed]) web page
------------------------------------------------------------
"Ask the Experts: Zoster" web page updated with new clinical considerations for vaccination of immunocompromised adults age 19 and older
Immunize.org has thoroughly reviewed and updated its popular Ask the Experts: Zoster ([link removed]) web page. This extensive list of clinical questions and answers was updated to incorporate new ACIP recommendations and clinical considerations for the use of recombinant zoster vaccine (RZV, Shingrix, GSK) in adults age 19 years and older who are or will be immunodeficient or immunosuppressed as a result of disease or therapy. The section addresses challenging clinical questions, such as:
* Do immunocompromised adults need to be screened for immunity to varicella zoster virus?
* What do I do with an adult who never had chickenpox and only had one dose of varicella vaccine?
* Should I shorten the dosing interval if a person knows they will be starting chemotherapy soon?
[link removed]
Immunize.org's Ask the Experts ([link removed]) main page leads you to 30 distinct web pages on a variety of topics with more than 1,100 common or challenging questions and answers about vaccines and their administration. Immunize.org's team of experts includes Kelly L. Moore, MD, MPH (team lead), Carolyn B. Bridges, MD, FACP, and Iyabode Beysolow, MD, MPH.
Related Links
* Immunize.org: Ask the Experts: Zoster ([link removed]) web page
* Immunize.org: Ask the Experts ([link removed]) main page to answer more than 1,100 questions
------------------------------------------------------------
Immunize.org posts new Vaccine Information Statements (VISs) in eight languages for pneumococcal conjugate vaccine (PCV) and recombinant zoster vaccine
Immunize.org posted new translations of Vaccine Information Statements ([link removed]) (VISs) for Pneumococcal Conjugate Vaccine (PCV) and Recombinant Zoster (shingles) Vaccine.
All translations are available in print-ready PDF format.
VIS translations for Pneumococcal Conjugate Vaccine (PCV) ([link removed]):
* Arabic ([link removed])
* Chinese in Simplified ([link removed]) and Traditional ([link removed])
* French ([link removed])
* Russian ([link removed])
* Somali ([link removed])
* Spanish PDF ([link removed]) and RTF ([link removed])
* Vietnamese ([link removed])
VIS translations for Recombinant Zoster (shingles) Vaccine ([link removed]):
* Arabic ([link removed])
* Chinese in Simplified ([link removed]) and Traditional ([link removed])
* French ([link removed])
* Russian ([link removed])
* Somali ([link removed])
* Spanish PDF ([link removed]) and RTF ([link removed])
* Vietnamese ([link removed])
Translations of previous VIS versions may be used until new translations become available. CDC states that the corresponding up-to-date English-language VIS must also be supplied when providing an out-of-date translation.
Related Links
* Immunize.org: Vaccine Information Statement ([link removed]) main page for VISs in 46 languages ([link removed])
* Immunize.org: Dates of Current Vaccine Information Statements ([link removed]) (PDF)
* CDC: What's New with VISs ([link removed]) web page
* CDC: Current VISs ([link removed]) web page
------------------------------------------------------------
Order today! Laminated versions of CDC’s 2022 immunization schedules will begin to ship this week.
Immunize.org laminated versions of the 2022 U.S. child and adolescent immunization schedule ([link removed]) and the 2022 U.S. adult immunization schedule ([link removed]) are available for preorder and will ship this week.
While the schedules are available online from CDC at no cost, Immunize.org’s printed, laminated schedules are ideal for use in any busy healthcare setting where vaccinations are given. Their tough coating can be wiped down, and they’re durable enough to stand up to a year's worth of use.
In 2022, the length of each schedule with appendices was extended by two pages. As a result, the laminated schedules are now published in a standard 8.5” X 11” booklet format.
* The child/adolescent schedule booklet is ten pages (i.e., five double-sided pages) and includes a bonus page with Immunize.org’s popular 1-page handout summarizing the dose, route, and needle size recommendations for all vaccines and recipients
* The adult schedule booklet is eight pages (i.e., four double-sided pages)
With color coding for easy reading, our laminated schedules replicate the original CDC formatting, including the essential tables and notes.
PRICING
Number of Copies Cost
1–4 copies $7.50 each
5–19 copies $5.50 each
20–99 copies $4.50 each
100–499 copies $4.00 each
500–999 copies $3.50 each
For quotes on customizing or placing orders of 1,000 copies or more, call 651-647-9009 or email [email protected].
Visit the Shop Immunize.org: Laminated Schedules ([link removed]) web page for more information on the schedules, to view images of all the pages, to download the order form, and to order today!
Related Links
* Immunize.org: Laminated Child and Adolescent Immunization Schedules (0–18 years) ([link removed]) web page
* Immunize.org: Laminated Adult Immunization Schedules (19 and older) ([link removed]) web page
* Immunize.org: Shop Immunize.org ([link removed]) main page
------------------------------------------------------------
“Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection among Children Aged 5–11 Years and Adolescents Aged 12–15 Years—PROTECT Cohort, July 2021–February 2022” published in MMWR
CDC published Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection among Children Aged 5–11 Years and Adolescents Aged 12–15 Years—PROTECT Cohort, July 2021–February 2022 ([link removed]) on March 11 in MMWR. A portion of the summary appears below.
Children and adolescents aged 5–15 years were tested for SARS-CoV-2 weekly, irrespective of symptoms, during July 2021–February 2022. Approximately one half of Omicron infections in unvaccinated children and adolescents were asymptomatic. Two doses of Pfizer-BioNTech COVID-19 vaccine reduced the risk of Omicron infection by 31% among children aged 5–11 years and by 59% among persons aged 12–15 years.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]).
Related Link
* MMWR's main page ([link removed]) provides access to MMWR Weekly and its companion publications
------------------------------------------------------------
CDC updates PneumoRecs VaxAdvisor mobile app for vaccine providers
CDC updated its PneumoRecs VaxAdvisor ([link removed]) mobile app to reflect ACIP’s new adult pneumococcal vaccination recommendations. Available for free on iOS and Android devices, the app helps vaccination providers quickly and easily determine which pneumococcal vaccine(s) a patient needs and when. The app incorporates recommendations for all ages so internists, family physicians, pediatricians, and pharmacists alike will find the tool beneficial.
Download the PneumoRecs VaxAdvisor ([link removed]) mobile app for free today.
------------------------------------------------------------
Unity Consortium launches Adolescent Immunization Action Week, April 4–8, with release of partner toolkit
Adolescent Immunization Action Week (AIAW) ([link removed]) was launched this year by Unity Consortium ([link removed]) to urge healthcare providers and parents to be sure adolescents receive all recommended immunizations. This first annual observance will be held April 4–8.
Unity created the Unity Partner Toolkits ([link removed]) website (password: unity) to help amplify messages to healthcare providers, parents, adolescents and young adults. Use these resources to help improve adolescent immunization coverage within your practice.
Visit Unity’s AIAW campaign page ([link removed]) for social media-ready materials you can use to draw attention to the importance of improving adolescent immunization coverage.
------------------------------------------------------------
Influenza season is not done yet; activity low but increased slightly in most of the country. Keep offering to vaccinate.
Influenza Surveillance
For week 9, ending on March 5, CDC's Weekly U.S. Influenza Surveillance Report, FluView ([link removed]) summary reports that seasonal influenza activity in the United States is low but increased slightly in most of the country. The levels of acute respiratory illness reflected in the national map include both influenza and non-influenza (e.g., COVID-19) respiratory illnesses.
Influenza Vaccination Dashboard
CDC's new Weekly Flu Vaccination Dashboard ([link removed]) shares preliminary vaccination data. This week’s key fact: flu vaccination coverage for children age 6 months to 17 years is 2.8 percentage points lower for all children this season as compared with last season and 4.4 percentage points lower for non-Hispanic White children this season compared with last season.
CDC recommends everyone age 6 months and older get an annual influenza vaccine. Influenza and COVID-19 vaccines may be given at the same visit, if needed. COVID-19 vaccination alone provides no protection from influenza or any other respiratory virus.
Vaccine Finder
If you don’t provide influenza vaccine at your site, please strongly recommend vaccination and refer people to sites that do vaccinate. Use VaccineFinder, a user-friendly website to help people of all ages find influenza, COVID-19, and other vaccines ([link removed]). Participating providers can update their vaccine inventory estimates on VaccineFinder. For questions or more information, contact [email protected] (mailto:[email protected]).
Related Links
* CDC: Weekly Flu Vaccination Dashboard ([link removed]) main page
* CDC: FluView ([link removed]) main page
* CDC: Influenza (Flu) ([link removed]) main page
* Immunize.org: free educational materials and patient handouts related to influenza ([link removed])
* Immunize.org: Vaccines: Influenza ([link removed]) main page
* Immunize.org: Ask the Experts: Influenza ([link removed]) main page
* VaccineFinder ([link removed]) website
* Families Fighting Flu: Flu Resources for Healthcare Professionals ([link removed]) main page
------------------------------------------------------------
HHS seeks stakeholder comments on its draft Vaccines Federal Implementation Plan 2021–2025; deadline March 29
On March 2, the U.S. Department of Health and Human Services (HHS) published a Request for Information (RFI) ([link removed]) to solicit written public comments on the draft Vaccines Federal Implementation Plan 2021–2025 ([link removed]). The Vaccines Federal Implementation Plan is a companion document to the Vaccines National Strategic Plan 2021–2025 ([link removed]) (VNSP), which was published in January 2021. The Vaccines Federal Implementation Plan is a compilation of federal agency vaccination activities that collectively advance the goals of the VNSP. Its target audience is other federal agencies and external partners who work in the area of vaccination.
The public comment period ([link removed]) for the Vaccines Federal Implementation Plan ends on March 29, 2022, at 5 p.m. (ET).
------------------------------------------------------------
Spotlight! Immunize.org's "Clinic Tools” main page is a one-stop source of practical information for vaccination providers
Immunize.org's Clinic Tools main page ([link removed]) is a collection of resources from Immunize.org, CDC, and other organizations related to practical, "how-to" information about providing vaccinations in a medical office or non-traditional setting. This page can be found by selecting the "Clinic Tools" tab in the middle of the blue banner atop every Immunize.org web page.
In the left-hand column, you will find links to Immunize.org's web pages on Administering Vaccines, Adolescent Vaccination, Adult Vaccination, Documenting Vaccination, Scheduling Vaccines, Screening for Contraindications, Storage and Handling, Vaccination and COVID-19, and Vaccine Recommendations.
The right-hand column features resources from partners, including CDC’s vaccine recommendations, “General Best Practice Guidelines for Immunization,” and The Epidemiology and Prevention of Vaccine-Preventable Diseases ("The Pink Book").
Visit the Clinic Tools main page ([link removed]) on Immunize.org.
Related Links
* Immunize.org: Clinic Tools ([link removed]) main page
* Immunize.org: Clinic Tools: Administering Vaccines ([link removed])
* Immunize.org: Clinic Tools: Adolescent Vaccination ([link removed])
* Immunize.org: Clinic Tools: Adult Vaccination ([link removed])
* Immunize.org: Clinic Tools: Documenting Vaccinations ([link removed])
* Immunize.org: Clinic Tools: Scheduling Vaccines ([link removed])
* Immunize.org: Clinic Tools: Screening for Vaccine Contraindications and Precautions ([link removed])
* Immunize.org: Clinic Tools: Storage and Handling ([link removed])
* Immunize.org: Clinic Tools: Vaccination and COVID-19 ([link removed])
* Immunize.org: Clinic Tools: Vaccine Recommendations ([link removed])
------------------------------------------------------------
Journalists interview Immunize.org experts
Journalists seek out Immunize.org experts to help explain vaccines to the public and policy makers. We help the media understand and communicate the complex work vaccinators do. Here is a recent citation.
* Salon: Experts Say Vaccine Effectiveness for Young Children Isn’t Waning, despite Some Reports ([link removed]) (3/6/22)
------------------------------------------------------------
Vaccines in the news
These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.
* Tampa Bay Times: COVID Researchers: Florida ‘Cherry-Picked’ Our Work in Kid Vaccine Recommendation ([link removed]) (3/11/2022)
* Time: Polio Makes a Comeback in Ukraine as War Halts Vaccination Campaign ([link removed]) (3/9/22)
* NPR: Bubbles, Breathwork or Bribery? If Your Kid Has Needle Phobia, Try These Tips ([link removed]) (3/8/22)
* FCAAP: FCAAP Statement regarding the COVID-19 Vaccine and Florida’s Children ([link removed]) (3/7/22)
* Medscape: Measles Drop in Pandemic May Generate False Sense of Security ([link removed]) (3/7/22)
* Vox: The Long, Strange History of Anti-vaccination Movements ([link removed]) (3/4/22)
------------------------------------------------------------
Immunize.org Pages and Handouts
------------------------------------------------------------
New! Keep up to date using Immunize.org’s new “Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools” and updated COVID-19 main page.
It is challenging to keep up with changes to COVID-19 vaccine guidance and the numerous fact sheets and job aids available. To address this, Immunize.org published a new 2-page job aid, Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools ([link removed]). The checklist includes the most recent revision dates of CDC’s primary COVID-19 vaccination websites, as well as print-ready PDF documents from CDC and FDA. Each date is hyperlinked to the original document or web page. Immunize.org will update this list at least monthly, prominently indicating when it was last updated at the top of the page. We encourage COVID-19 vaccination providers to review this list monthly to be sure your practices stay up to date.
In addition, Immunize.org updated its Vaccines: COVID-19 ([link removed]) main page, which provides a comprehensive index to key resources from CDC, Immunize.org, and other partners. This page facilitates access to information on COVID-19 vaccine products, clinic resources and tools, vaccine fact sheets, and other important vaccine-related topics. Links just added to this web page include the new checklist described above and CDC’s Interim COVID-19 Vaccine Immunization Schedule for Ages 5 Years and Older ([link removed]).
Related Links
* Immunize.org: Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools ([link removed])(PDF)
* Immunize.org: Vaccines: COVID-19 ([link removed]) main page
* Immunize.org: Ask the Experts: COVID-19 ([link removed]) web page
* CDC: Interim Clinical Considerations for Use of COVID-19 Vaccines ([link removed]) main page
------------------------------------------------------------
"Ask the Experts: COVID-19" web page updated with newest CDC clinical considerations, including expanded dose intervals for mRNA vaccines
Immunize.org published a thoroughly updated version of its popular Ask the Experts: COVID-19 ([link removed]) web page, current as of February 24. This extensive list of clinical questions and answers addresses COVID-19 recommendations and clinical considerations, including new CDC guidance issued in February. New and updated questions will address such issues as:
* Who should wait 8 weeks between mRNA primary series doses?
* What should we do with a patient who, as part of a clinical trial, received a vaccine not yet routinely used in other countries?
* Is there no longer a waiting period after antibody treatment of COVID-19 infection before COVID-19 vaccination?
* How long should someone wait after vaccination to receive an antibody infusion for pre-exposure prophylaxis?
Immunize.org's Ask the Experts ([link removed]) main page leads you to 30 distinct web pages on a variety of topics with more than 1,100 common or challenging questions and answers about vaccines and their administration. Immunize.org's team of experts includes Kelly L. Moore, MD, MPH (team lead), Carolyn B. Bridges, MD, FACP, and Iyabode Beysolow, MD, MPH.
Related Links
* Immunize.org: Ask the Experts: COVID-19 ([link removed]) web page
* Immunize.org: Ask the Experts ([link removed]) main page to answer more than 1,100 questions
------------------------------------------------------------
Visit Immunize.org's “Vaccines: COVID-19” main page to locate the latest information on COVID-19 vaccines
Be sure to bookmark Immunize.org's Vaccines: COVID-19 ([link removed]) main page for quick access to links to key COVID-19 vaccine resource pages from Immunize.org, CDC, and other partners.
As policies for COVID-19 vaccines are updated and new CDC materials are released,
Immunize.org's Vaccines: COVID-19 ([link removed]) main page and resources will continue to be updated.
------------------------------------------------------------
Featured Resources
------------------------------------------------------------
65+ Flu Defense website offers resources for healthcare professionals serving older adults
Confident recommendations for influenza vaccine from healthcare providers are powerfully persuasive. To assist you in maximizing protection for your patients, Immunize.org, in collaboration with Seqirus, has updated the 65+ Flu Defense website at www.influenza-defense.org.
A fact sheet on the site, The Importance of Preventing Influenza during a Pandemic ([link removed]) , offers responses to help guide discussions with patients on the increased importance of flu vaccination during the COVID-19 pandemic. Age increases risks associated with COVID-19 infection including hospitalization and death. Preliminary studies suggest coinfection with influenza B and SARS-CoV-2 may elevate the risk of poor outcomes.
This helpful site includes information, tools, and tips for communicating with these adults about the scope and severity of influenza. Resources include:
* Influenza in Adults 65+: The Facts ([link removed])
* Influenza Vaccination: Questions Patients Age 65 and Older Frequently Ask Their HCP ([link removed])
Check out the updated 65+ Flu Defense website at www.influenza-defense.org ([link removed]) to assist your efforts in protecting this vulnerable population.
------------------------------------------------------------
Use Immunize.org’s Vaccinating Adults: A Step-by-Step Guide—free to download by chapter or in its entirety.
Download Immunize.org’s free 142-page book on adult vaccination, to help build your program and train your team: Vaccinating Adults: A Step-by-Step Guide (Guide) ([link removed]).
This thorough "how to" guide on adult vaccination provides easy-to-use, practical information covering all essential activities. It helps vaccine providers enhance their existing adult vaccination services or introduce them into any clinical setting.
The Guide is available to download/print either by chapter or in its entirety free at www.immunize.org/guide. The National Vaccine Program Office and CDC both supported the development of the Guide and provided early technical review.
The Guide is a valuable resource to assist providers in increasing adult vaccination rates. Be sure to get a copy today!
Please note: this guide was produced in 2017, before the COVID-19 era, and reflects the recommendations of that time.
Related Links
* Vaccinating Adults: A Step-by-Step Guide ([link removed]) main page, permitting download of entire Guide (142 pages, PDF) ([link removed])
* View the table of contents and individual chapters (PDF):
+ Table of Contents ([link removed])
+ Step 1: Getting Started ([link removed])
+ Step 2: Setting Up for Vaccination Services ([link removed])
+ Step 3: Vaccine Storage and Handling ([link removed])
+ Step 4: Deciding Whom to Vaccinate ([link removed])
+ Step 5: Administering Vaccines ([link removed])
+ Step 6: Documentation and Related Issues ([link removed])
+ Step 7A: Financial Considerations ([link removed])
+ Step 7B: How to Bill for Adult Immunizations ([link removed])
* Immunize.org’s educational materials (handouts) on adult immunization ([link removed])
------------------------------------------------------------
Notable Publications
------------------------------------------------------------
“Interim Estimates of 2021–22 Seasonal Influenza Vaccine Effectiveness—United States, February 2022” published in MMWR
CDC published Interim Estimates of 2021–22 Seasonal Influenza Vaccine Effectiveness—United States, February 2022 ([link removed]) on March 11 in MMWR. A portion of the summary appears below.
Based on data from 3,636 children, adolescents, and adults with acute respiratory infection during October 4, 2021–February 12, 2022, seasonal influenza vaccination did not reduce the risk for outpatient respiratory illness caused by influenza A(H3N2) viruses that have predominated so far this season. …
CDC recommends influenza vaccination for as long as influenza viruses are circulating. Vaccination can prevent serious influenza-related complications caused by viruses that might circulate later in the season, including 2009 pandemic A(H1N1) and influenza B viruses.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]).
Related Link
* MMWR's main page ([link removed]) provides access to MMWR Weekly and its companion publications
------------------------------------------------------------
“COVID-19 Vaccine Provider Access and Vaccination Coverage among Children Aged 5–11 Years—United States, November 2021–January 2022” published in MMWR
CDC published COVID-19 Vaccine Provider Access and Vaccination Coverage among Children Aged 5–11 Years—United States, November 2021–January 2022 ([link removed]) on March 11 in MMWR. A portion of the summary appears below.
At 11 weeks after launch of the pediatric COVID-19 vaccination program, 92% of children aged 5–11 years lived within 5 miles (8 km) of a pediatric vaccine provider; 44% of providers were pharmacies. COVID-19 first-dose vaccination coverage rates were low, particularly in high social vulnerability index (SVI) areas, but improved over time. …
Broad vaccine access should be maintained while critical outreach efforts continue to improve vaccine coverage among children aged 5–11 years, especially in high SVI areas. If COVID-19 vaccine is recommended for children aged <5 years, similar efforts to strategically maximize access and coverage might be considered.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]).
Related Link
* MMWR's main page ([link removed]) provides access to MMWR Weekly and its companion publications
------------------------------------------------------------
MMWR Recap: Articles regarding COVID-19 vaccine effectiveness and safety monitoring
CDC recently published several articles first distributed as MMWR Early Releases:
* Safety Monitoring of COVID-19 Vaccine Booster Doses among Persons Aged 12–17 Years—United States, December 9, 2021–February 20, 2022 (MMWR, March 4, HTML ([link removed]) or PDF ([link removed]) )
* Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations among Nonimmunocompromised Children and Adolescents Aged 5–17 Years—VISION Network, 10 States, April 2021–January 2022 (MMWR, March 4, HTML ([link removed]) or PDF ([link removed]) )
Related Link
* MMWR ([link removed]) main page provides access to MMWR Weekly and its companion publications
------------------------------------------------------------
Global News
------------------------------------------------------------
WHO confirms circulating vaccine-derived poliovirus in Israel
WHO published an update to their web page titled Circulating Vaccine-Derived Poliovirus Confirmed in Israel and the Occupied Palestinian Territory ([link removed]). A portion of the web page appears below.
On Monday, 7 March 2022, a case of circulating vaccine-derived poliovirus type 3 (cVDPV3) was confirmed in an unvaccinated girl aged 3 years and 9 months in Israel. The girl had developed acute flaccid paralysis and, upon testing of her stool, poliovirus was confirmed.
Further testing of the poliovirus isolated from the girl revealed genetic links to VDPV3 strains detected in environmental samples collected from sites in Israel and the occupied Palestinian territory between September 2021 and January 2022. These isolates, previously classified as ambiguous VDPV3, have now been reclassified as circulating VDPV3 (cVDPV3). This confirms an outbreak of cVDPV3 in both Israel and the occupied Palestinian territory.
------------------------------------------------------------
Upcoming Events
------------------------------------------------------------
Virtual: NFID hosts "Updates from Recent Advisory Committee on Immunization Practices (ACIP) Meetings" webinar on March 17
The National Foundation for Infectious Diseases (NFID) will offer a webinar titled Updates from Recent Advisory Committee on Immunization Practices (ACIP) Meetings ([link removed]) on March 17 at 1:00 p.m. (ET). During this program, William Schaffner, MD, NFID medical director and ACIP liaison, and Jessica MacNeil, MPH, ACIP deputy executive secretary, CDC, will discuss the latest updates including current U.S. vaccination recommendations for children, adolescents, and adults.
There is no fee to participate in this activity, but pre-registration is required ([link removed]).
------------------------------------------------------------
Virtual and In Person: Registration open for "North Dakota Immunization Conference" on June 21–22; CE available
The North Dakota Immunization Conference ([link removed]) will take place virtually and in person on June 21–22 in Bismarck, North Dakota. Conference objectives are to explore strategies and best practices to increase immunization coverage rates; evaluate communication strategies for responding to questions from patients/families; and discuss updates to the child, adolescent, and adult immunization schedule.
Continuing education credits are pending.
There is a $100 fee to attend. The fee increases to $150 after May 30.
View the schedule here ([link removed]). Register for the event ([link removed]).
------------------------------------------------------------
For more upcoming events, visit our Calendar of Events ([link removed]).
Editorial Information
Editor-in-Chief
Kelly L. Moore, MD, MPH
Managing Editor
John D. Grabenstein, RPh, PhD
Associate Editor
Sharon G. Humiston, MD, MPH
Writer/Publication Coordinator
Taryn Chapman, MS
Courtnay Londo, MA
Style and Copy Editor
Marian Deegan, JD
Web Edition Managers
Arkady Shakhnovich
Jermaine Royes
Contributing Writer
Laurel H. Wood, MPA
Technical Reviewer
Robin VanOss
About IZ Express
Immunize.org welcomes redistribution of this issue of IZ Express or selected articles. When you do so, please add a note that Immunize.org is the source of the material and provide a link to this issue ([link removed]).
IZ Express is supported in part by Grant No. 1NH23IP922654 from the National Center for Immunization and Respiratory Diseases, CDC. Its contents are solely the responsibility of Immunize.org and do not necessarily represent the official views of CDC.
IZ Express Disclaimer ([link removed])
ISSN: 2771-8085
To unsubscribe to this publication, go to: [link removed]
==============================================
Unsubscribe [email protected] from this list:
[link removed]
[link removed]
[link removed]
[link removed] [link removed]
Email not displaying correctly? View it in your browser ([link removed]).
[link removed]
Issue 1,621: March 16, 2022 Formerly IAC Express
Top Stories
* Immunize.org updates two of its popular standing order templates with new CDC recommendations: pneumococcal vaccination of adults and zoster (shingles) vaccination
* "Ask the Experts: Zoster" web page updated with new clinical considerations for vaccination of immunocompromised adults age 19 and older
* Immunize.org posts new Vaccine Information Statements (VISs) in eight languages for pneumococcal conjugate vaccine (PCV) and recombinant zoster vaccine
* Order today! Laminated versions of CDC’s 2022 immunization schedules will begin to ship this week.
* “Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection among Children Aged 5–11 Years and Adolescents Aged 12–15 Years—PROTECT Cohort, July 2021–February 2022” published in MMWR
* CDC updates PneumoRecs VaxAdvisor mobile app for vaccine providers
* Unity Consortium launches Adolescent Immunization Action Week, April 4–8, with release of partner toolkit
* Influenza season is not done yet; activity low but increased slightly in most of the country. Keep offering to vaccinate.
* HHS seeks stakeholder comments on its draft Vaccines Federal Implementation Plan 2021–2025; deadline March 29
* Spotlight! Immunize.org's "Clinic Tools” main page is a one-stop source of practical information for vaccination providers
* Journalists interview Immunize.org experts
* Vaccines in the news
Immunize.org Pages and Handouts
* New! Keep up to date using Immunize.org’s new “Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools” and updated COVID-19 main page.
* "Ask the Experts: COVID-19" web page updated with newest CDC clinical considerations, including expanded dose intervals for mRNA vaccines
* Visit Immunize.org's “Vaccines: COVID-19” main page to locate the latest information on COVID-19 vaccines
Featured Resources
* 65+ Flu Defense website offers resources for healthcare professionals serving older adults
* Use Immunize.org's Vaccinating Adults: A Step-by-Step Guide—free to download by chapter or in its entirety.
Notable Publications
* “Interim Estimates of 2021–22 Seasonal Influenza Vaccine Effectiveness—United States, February 2022” published in MMWR
* “COVID-19 Vaccine Provider Access and Vaccination Coverage among Children Aged 5–11 Years—United States, November 2021–January 2022” published in MMWR
* MMWR Recap: Articles regarding COVID-19 vaccine effectiveness and safety monitoring
Global News
* WHO confirms circulating vaccine-derived poliovirus in Israel
Upcoming Events
* Virtual: NFID hosts "Updates from Recent Advisory Committee on Immunization Practices (ACIP) Meetings" webinar on March 17
* Virtual and In Person: Registration open for "North Dakota Immunization Conference" on June 21–22; CE available
------------------------------------------------------------
Top Stories
------------------------------------------------------------
Immunize.org updates two of its popular standing order templates with new CDC recommendations: pneumococcal vaccination of adults and zoster (shingles) vaccination
Immunize.org recently revised its Standing Orders for Administering Pneumococcal Vaccines (PCV15, PCV20, and PPSV23) to Adults ([link removed]) and Standing Orders for Administering Recombinant Zoster Vaccine to Adults ([link removed]) templates.
The Standing Orders for Administering Pneumococcal Vaccines (PCV15, PCV20, and PPSV23) to Adults ([link removed]) template incorporates the new CDC recommendations published in January 2022. This template covers the use of 15-valent pneumococcal conjugate vaccine (PCV15, Vaxneuvance, Merck), PCV20 (Prevnar20, Pfizer), and 23-valent pneumococcal polysaccharide vaccine (PPSV23, Pneumovax 23, Merck). The document outlines what to do for previously unvaccinated adults, as well as adults with a history of vaccination with PCV13 and/or PPSV23.
The Standing Orders for Administering Recombinant Zoster Vaccine to Adults ([link removed]) template was updated with information on the new CDC recommendations for use of recombinant zoster vaccine (RZV, Shingrix, GSK) in adults age 19 and older who are or will be immunodeficient or immunosuppressed as a result of disease or therapy. For patients in this category, the standing orders recommend consultation with the medical director and—as needed—the provider primarily responsible for managing the patient’s immunocompromising condition or therapy. This is because the complex and highly variable nature of immunocompromising conditions may affect the optimal timing of vaccination.
Related Links
* Immunize.org: Standing Orders for Administering Pneumococcal Vaccines (PCV15, PCV20, and PPSV23) to Adults ([link removed])
* Immunize.org: Standing Orders for Administering Recombinant Zoster Vaccine to Adults ([link removed])
* Immunize.org: Using Standing Orders for Administering Vaccines: What You Should Know ([link removed])
* Immunize.org: 10 Steps to Implementing Standing Orders for Immunization in Your Practice Setting ([link removed])
* Immunize.org: Standing Orders Templates for Administering Vaccines ([link removed]) web page
* Immunize.org: Ask the Experts: Zoster ([link removed]) web page
------------------------------------------------------------
"Ask the Experts: Zoster" web page updated with new clinical considerations for vaccination of immunocompromised adults age 19 and older
Immunize.org has thoroughly reviewed and updated its popular Ask the Experts: Zoster ([link removed]) web page. This extensive list of clinical questions and answers was updated to incorporate new ACIP recommendations and clinical considerations for the use of recombinant zoster vaccine (RZV, Shingrix, GSK) in adults age 19 years and older who are or will be immunodeficient or immunosuppressed as a result of disease or therapy. The section addresses challenging clinical questions, such as:
* Do immunocompromised adults need to be screened for immunity to varicella zoster virus?
* What do I do with an adult who never had chickenpox and only had one dose of varicella vaccine?
* Should I shorten the dosing interval if a person knows they will be starting chemotherapy soon?
[link removed]
Immunize.org's Ask the Experts ([link removed]) main page leads you to 30 distinct web pages on a variety of topics with more than 1,100 common or challenging questions and answers about vaccines and their administration. Immunize.org's team of experts includes Kelly L. Moore, MD, MPH (team lead), Carolyn B. Bridges, MD, FACP, and Iyabode Beysolow, MD, MPH.
Related Links
* Immunize.org: Ask the Experts: Zoster ([link removed]) web page
* Immunize.org: Ask the Experts ([link removed]) main page to answer more than 1,100 questions
------------------------------------------------------------
Immunize.org posts new Vaccine Information Statements (VISs) in eight languages for pneumococcal conjugate vaccine (PCV) and recombinant zoster vaccine
Immunize.org posted new translations of Vaccine Information Statements ([link removed]) (VISs) for Pneumococcal Conjugate Vaccine (PCV) and Recombinant Zoster (shingles) Vaccine.
All translations are available in print-ready PDF format.
VIS translations for Pneumococcal Conjugate Vaccine (PCV) ([link removed]):
* Arabic ([link removed])
* Chinese in Simplified ([link removed]) and Traditional ([link removed])
* French ([link removed])
* Russian ([link removed])
* Somali ([link removed])
* Spanish PDF ([link removed]) and RTF ([link removed])
* Vietnamese ([link removed])
VIS translations for Recombinant Zoster (shingles) Vaccine ([link removed]):
* Arabic ([link removed])
* Chinese in Simplified ([link removed]) and Traditional ([link removed])
* French ([link removed])
* Russian ([link removed])
* Somali ([link removed])
* Spanish PDF ([link removed]) and RTF ([link removed])
* Vietnamese ([link removed])
Translations of previous VIS versions may be used until new translations become available. CDC states that the corresponding up-to-date English-language VIS must also be supplied when providing an out-of-date translation.
Related Links
* Immunize.org: Vaccine Information Statement ([link removed]) main page for VISs in 46 languages ([link removed])
* Immunize.org: Dates of Current Vaccine Information Statements ([link removed]) (PDF)
* CDC: What's New with VISs ([link removed]) web page
* CDC: Current VISs ([link removed]) web page
------------------------------------------------------------
Order today! Laminated versions of CDC’s 2022 immunization schedules will begin to ship this week.
Immunize.org laminated versions of the 2022 U.S. child and adolescent immunization schedule ([link removed]) and the 2022 U.S. adult immunization schedule ([link removed]) are available for preorder and will ship this week.
While the schedules are available online from CDC at no cost, Immunize.org’s printed, laminated schedules are ideal for use in any busy healthcare setting where vaccinations are given. Their tough coating can be wiped down, and they’re durable enough to stand up to a year's worth of use.
In 2022, the length of each schedule with appendices was extended by two pages. As a result, the laminated schedules are now published in a standard 8.5” X 11” booklet format.
* The child/adolescent schedule booklet is ten pages (i.e., five double-sided pages) and includes a bonus page with Immunize.org’s popular 1-page handout summarizing the dose, route, and needle size recommendations for all vaccines and recipients
* The adult schedule booklet is eight pages (i.e., four double-sided pages)
With color coding for easy reading, our laminated schedules replicate the original CDC formatting, including the essential tables and notes.
PRICING
Number of Copies Cost
1–4 copies $7.50 each
5–19 copies $5.50 each
20–99 copies $4.50 each
100–499 copies $4.00 each
500–999 copies $3.50 each
For quotes on customizing or placing orders of 1,000 copies or more, call 651-647-9009 or email [email protected].
Visit the Shop Immunize.org: Laminated Schedules ([link removed]) web page for more information on the schedules, to view images of all the pages, to download the order form, and to order today!
Related Links
* Immunize.org: Laminated Child and Adolescent Immunization Schedules (0–18 years) ([link removed]) web page
* Immunize.org: Laminated Adult Immunization Schedules (19 and older) ([link removed]) web page
* Immunize.org: Shop Immunize.org ([link removed]) main page
------------------------------------------------------------
“Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection among Children Aged 5–11 Years and Adolescents Aged 12–15 Years—PROTECT Cohort, July 2021–February 2022” published in MMWR
CDC published Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection among Children Aged 5–11 Years and Adolescents Aged 12–15 Years—PROTECT Cohort, July 2021–February 2022 ([link removed]) on March 11 in MMWR. A portion of the summary appears below.
Children and adolescents aged 5–15 years were tested for SARS-CoV-2 weekly, irrespective of symptoms, during July 2021–February 2022. Approximately one half of Omicron infections in unvaccinated children and adolescents were asymptomatic. Two doses of Pfizer-BioNTech COVID-19 vaccine reduced the risk of Omicron infection by 31% among children aged 5–11 years and by 59% among persons aged 12–15 years.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]).
Related Link
* MMWR's main page ([link removed]) provides access to MMWR Weekly and its companion publications
------------------------------------------------------------
CDC updates PneumoRecs VaxAdvisor mobile app for vaccine providers
CDC updated its PneumoRecs VaxAdvisor ([link removed]) mobile app to reflect ACIP’s new adult pneumococcal vaccination recommendations. Available for free on iOS and Android devices, the app helps vaccination providers quickly and easily determine which pneumococcal vaccine(s) a patient needs and when. The app incorporates recommendations for all ages so internists, family physicians, pediatricians, and pharmacists alike will find the tool beneficial.
Download the PneumoRecs VaxAdvisor ([link removed]) mobile app for free today.
------------------------------------------------------------
Unity Consortium launches Adolescent Immunization Action Week, April 4–8, with release of partner toolkit
Adolescent Immunization Action Week (AIAW) ([link removed]) was launched this year by Unity Consortium ([link removed]) to urge healthcare providers and parents to be sure adolescents receive all recommended immunizations. This first annual observance will be held April 4–8.
Unity created the Unity Partner Toolkits ([link removed]) website (password: unity) to help amplify messages to healthcare providers, parents, adolescents and young adults. Use these resources to help improve adolescent immunization coverage within your practice.
Visit Unity’s AIAW campaign page ([link removed]) for social media-ready materials you can use to draw attention to the importance of improving adolescent immunization coverage.
------------------------------------------------------------
Influenza season is not done yet; activity low but increased slightly in most of the country. Keep offering to vaccinate.
Influenza Surveillance
For week 9, ending on March 5, CDC's Weekly U.S. Influenza Surveillance Report, FluView ([link removed]) summary reports that seasonal influenza activity in the United States is low but increased slightly in most of the country. The levels of acute respiratory illness reflected in the national map include both influenza and non-influenza (e.g., COVID-19) respiratory illnesses.
Influenza Vaccination Dashboard
CDC's new Weekly Flu Vaccination Dashboard ([link removed]) shares preliminary vaccination data. This week’s key fact: flu vaccination coverage for children age 6 months to 17 years is 2.8 percentage points lower for all children this season as compared with last season and 4.4 percentage points lower for non-Hispanic White children this season compared with last season.
CDC recommends everyone age 6 months and older get an annual influenza vaccine. Influenza and COVID-19 vaccines may be given at the same visit, if needed. COVID-19 vaccination alone provides no protection from influenza or any other respiratory virus.
Vaccine Finder
If you don’t provide influenza vaccine at your site, please strongly recommend vaccination and refer people to sites that do vaccinate. Use VaccineFinder, a user-friendly website to help people of all ages find influenza, COVID-19, and other vaccines ([link removed]). Participating providers can update their vaccine inventory estimates on VaccineFinder. For questions or more information, contact [email protected] (mailto:[email protected]).
Related Links
* CDC: Weekly Flu Vaccination Dashboard ([link removed]) main page
* CDC: FluView ([link removed]) main page
* CDC: Influenza (Flu) ([link removed]) main page
* Immunize.org: free educational materials and patient handouts related to influenza ([link removed])
* Immunize.org: Vaccines: Influenza ([link removed]) main page
* Immunize.org: Ask the Experts: Influenza ([link removed]) main page
* VaccineFinder ([link removed]) website
* Families Fighting Flu: Flu Resources for Healthcare Professionals ([link removed]) main page
------------------------------------------------------------
HHS seeks stakeholder comments on its draft Vaccines Federal Implementation Plan 2021–2025; deadline March 29
On March 2, the U.S. Department of Health and Human Services (HHS) published a Request for Information (RFI) ([link removed]) to solicit written public comments on the draft Vaccines Federal Implementation Plan 2021–2025 ([link removed]). The Vaccines Federal Implementation Plan is a companion document to the Vaccines National Strategic Plan 2021–2025 ([link removed]) (VNSP), which was published in January 2021. The Vaccines Federal Implementation Plan is a compilation of federal agency vaccination activities that collectively advance the goals of the VNSP. Its target audience is other federal agencies and external partners who work in the area of vaccination.
The public comment period ([link removed]) for the Vaccines Federal Implementation Plan ends on March 29, 2022, at 5 p.m. (ET).
------------------------------------------------------------
Spotlight! Immunize.org's "Clinic Tools” main page is a one-stop source of practical information for vaccination providers
Immunize.org's Clinic Tools main page ([link removed]) is a collection of resources from Immunize.org, CDC, and other organizations related to practical, "how-to" information about providing vaccinations in a medical office or non-traditional setting. This page can be found by selecting the "Clinic Tools" tab in the middle of the blue banner atop every Immunize.org web page.
In the left-hand column, you will find links to Immunize.org's web pages on Administering Vaccines, Adolescent Vaccination, Adult Vaccination, Documenting Vaccination, Scheduling Vaccines, Screening for Contraindications, Storage and Handling, Vaccination and COVID-19, and Vaccine Recommendations.
The right-hand column features resources from partners, including CDC’s vaccine recommendations, “General Best Practice Guidelines for Immunization,” and The Epidemiology and Prevention of Vaccine-Preventable Diseases ("The Pink Book").
Visit the Clinic Tools main page ([link removed]) on Immunize.org.
Related Links
* Immunize.org: Clinic Tools ([link removed]) main page
* Immunize.org: Clinic Tools: Administering Vaccines ([link removed])
* Immunize.org: Clinic Tools: Adolescent Vaccination ([link removed])
* Immunize.org: Clinic Tools: Adult Vaccination ([link removed])
* Immunize.org: Clinic Tools: Documenting Vaccinations ([link removed])
* Immunize.org: Clinic Tools: Scheduling Vaccines ([link removed])
* Immunize.org: Clinic Tools: Screening for Vaccine Contraindications and Precautions ([link removed])
* Immunize.org: Clinic Tools: Storage and Handling ([link removed])
* Immunize.org: Clinic Tools: Vaccination and COVID-19 ([link removed])
* Immunize.org: Clinic Tools: Vaccine Recommendations ([link removed])
------------------------------------------------------------
Journalists interview Immunize.org experts
Journalists seek out Immunize.org experts to help explain vaccines to the public and policy makers. We help the media understand and communicate the complex work vaccinators do. Here is a recent citation.
* Salon: Experts Say Vaccine Effectiveness for Young Children Isn’t Waning, despite Some Reports ([link removed]) (3/6/22)
------------------------------------------------------------
Vaccines in the news
These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.
* Tampa Bay Times: COVID Researchers: Florida ‘Cherry-Picked’ Our Work in Kid Vaccine Recommendation ([link removed]) (3/11/2022)
* Time: Polio Makes a Comeback in Ukraine as War Halts Vaccination Campaign ([link removed]) (3/9/22)
* NPR: Bubbles, Breathwork or Bribery? If Your Kid Has Needle Phobia, Try These Tips ([link removed]) (3/8/22)
* FCAAP: FCAAP Statement regarding the COVID-19 Vaccine and Florida’s Children ([link removed]) (3/7/22)
* Medscape: Measles Drop in Pandemic May Generate False Sense of Security ([link removed]) (3/7/22)
* Vox: The Long, Strange History of Anti-vaccination Movements ([link removed]) (3/4/22)
------------------------------------------------------------
Immunize.org Pages and Handouts
------------------------------------------------------------
New! Keep up to date using Immunize.org’s new “Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools” and updated COVID-19 main page.
It is challenging to keep up with changes to COVID-19 vaccine guidance and the numerous fact sheets and job aids available. To address this, Immunize.org published a new 2-page job aid, Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools ([link removed]). The checklist includes the most recent revision dates of CDC’s primary COVID-19 vaccination websites, as well as print-ready PDF documents from CDC and FDA. Each date is hyperlinked to the original document or web page. Immunize.org will update this list at least monthly, prominently indicating when it was last updated at the top of the page. We encourage COVID-19 vaccination providers to review this list monthly to be sure your practices stay up to date.
In addition, Immunize.org updated its Vaccines: COVID-19 ([link removed]) main page, which provides a comprehensive index to key resources from CDC, Immunize.org, and other partners. This page facilitates access to information on COVID-19 vaccine products, clinic resources and tools, vaccine fact sheets, and other important vaccine-related topics. Links just added to this web page include the new checklist described above and CDC’s Interim COVID-19 Vaccine Immunization Schedule for Ages 5 Years and Older ([link removed]).
Related Links
* Immunize.org: Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools ([link removed])(PDF)
* Immunize.org: Vaccines: COVID-19 ([link removed]) main page
* Immunize.org: Ask the Experts: COVID-19 ([link removed]) web page
* CDC: Interim Clinical Considerations for Use of COVID-19 Vaccines ([link removed]) main page
------------------------------------------------------------
"Ask the Experts: COVID-19" web page updated with newest CDC clinical considerations, including expanded dose intervals for mRNA vaccines
Immunize.org published a thoroughly updated version of its popular Ask the Experts: COVID-19 ([link removed]) web page, current as of February 24. This extensive list of clinical questions and answers addresses COVID-19 recommendations and clinical considerations, including new CDC guidance issued in February. New and updated questions will address such issues as:
* Who should wait 8 weeks between mRNA primary series doses?
* What should we do with a patient who, as part of a clinical trial, received a vaccine not yet routinely used in other countries?
* Is there no longer a waiting period after antibody treatment of COVID-19 infection before COVID-19 vaccination?
* How long should someone wait after vaccination to receive an antibody infusion for pre-exposure prophylaxis?
Immunize.org's Ask the Experts ([link removed]) main page leads you to 30 distinct web pages on a variety of topics with more than 1,100 common or challenging questions and answers about vaccines and their administration. Immunize.org's team of experts includes Kelly L. Moore, MD, MPH (team lead), Carolyn B. Bridges, MD, FACP, and Iyabode Beysolow, MD, MPH.
Related Links
* Immunize.org: Ask the Experts: COVID-19 ([link removed]) web page
* Immunize.org: Ask the Experts ([link removed]) main page to answer more than 1,100 questions
------------------------------------------------------------
Visit Immunize.org's “Vaccines: COVID-19” main page to locate the latest information on COVID-19 vaccines
Be sure to bookmark Immunize.org's Vaccines: COVID-19 ([link removed]) main page for quick access to links to key COVID-19 vaccine resource pages from Immunize.org, CDC, and other partners.
As policies for COVID-19 vaccines are updated and new CDC materials are released,
Immunize.org's Vaccines: COVID-19 ([link removed]) main page and resources will continue to be updated.
------------------------------------------------------------
Featured Resources
------------------------------------------------------------
65+ Flu Defense website offers resources for healthcare professionals serving older adults
Confident recommendations for influenza vaccine from healthcare providers are powerfully persuasive. To assist you in maximizing protection for your patients, Immunize.org, in collaboration with Seqirus, has updated the 65+ Flu Defense website at www.influenza-defense.org.
A fact sheet on the site, The Importance of Preventing Influenza during a Pandemic ([link removed]) , offers responses to help guide discussions with patients on the increased importance of flu vaccination during the COVID-19 pandemic. Age increases risks associated with COVID-19 infection including hospitalization and death. Preliminary studies suggest coinfection with influenza B and SARS-CoV-2 may elevate the risk of poor outcomes.
This helpful site includes information, tools, and tips for communicating with these adults about the scope and severity of influenza. Resources include:
* Influenza in Adults 65+: The Facts ([link removed])
* Influenza Vaccination: Questions Patients Age 65 and Older Frequently Ask Their HCP ([link removed])
Check out the updated 65+ Flu Defense website at www.influenza-defense.org ([link removed]) to assist your efforts in protecting this vulnerable population.
------------------------------------------------------------
Use Immunize.org’s Vaccinating Adults: A Step-by-Step Guide—free to download by chapter or in its entirety.
Download Immunize.org’s free 142-page book on adult vaccination, to help build your program and train your team: Vaccinating Adults: A Step-by-Step Guide (Guide) ([link removed]).
This thorough "how to" guide on adult vaccination provides easy-to-use, practical information covering all essential activities. It helps vaccine providers enhance their existing adult vaccination services or introduce them into any clinical setting.
The Guide is available to download/print either by chapter or in its entirety free at www.immunize.org/guide. The National Vaccine Program Office and CDC both supported the development of the Guide and provided early technical review.
The Guide is a valuable resource to assist providers in increasing adult vaccination rates. Be sure to get a copy today!
Please note: this guide was produced in 2017, before the COVID-19 era, and reflects the recommendations of that time.
Related Links
* Vaccinating Adults: A Step-by-Step Guide ([link removed]) main page, permitting download of entire Guide (142 pages, PDF) ([link removed])
* View the table of contents and individual chapters (PDF):
+ Table of Contents ([link removed])
+ Step 1: Getting Started ([link removed])
+ Step 2: Setting Up for Vaccination Services ([link removed])
+ Step 3: Vaccine Storage and Handling ([link removed])
+ Step 4: Deciding Whom to Vaccinate ([link removed])
+ Step 5: Administering Vaccines ([link removed])
+ Step 6: Documentation and Related Issues ([link removed])
+ Step 7A: Financial Considerations ([link removed])
+ Step 7B: How to Bill for Adult Immunizations ([link removed])
* Immunize.org’s educational materials (handouts) on adult immunization ([link removed])
------------------------------------------------------------
Notable Publications
------------------------------------------------------------
“Interim Estimates of 2021–22 Seasonal Influenza Vaccine Effectiveness—United States, February 2022” published in MMWR
CDC published Interim Estimates of 2021–22 Seasonal Influenza Vaccine Effectiveness—United States, February 2022 ([link removed]) on March 11 in MMWR. A portion of the summary appears below.
Based on data from 3,636 children, adolescents, and adults with acute respiratory infection during October 4, 2021–February 12, 2022, seasonal influenza vaccination did not reduce the risk for outpatient respiratory illness caused by influenza A(H3N2) viruses that have predominated so far this season. …
CDC recommends influenza vaccination for as long as influenza viruses are circulating. Vaccination can prevent serious influenza-related complications caused by viruses that might circulate later in the season, including 2009 pandemic A(H1N1) and influenza B viruses.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]).
Related Link
* MMWR's main page ([link removed]) provides access to MMWR Weekly and its companion publications
------------------------------------------------------------
“COVID-19 Vaccine Provider Access and Vaccination Coverage among Children Aged 5–11 Years—United States, November 2021–January 2022” published in MMWR
CDC published COVID-19 Vaccine Provider Access and Vaccination Coverage among Children Aged 5–11 Years—United States, November 2021–January 2022 ([link removed]) on March 11 in MMWR. A portion of the summary appears below.
At 11 weeks after launch of the pediatric COVID-19 vaccination program, 92% of children aged 5–11 years lived within 5 miles (8 km) of a pediatric vaccine provider; 44% of providers were pharmacies. COVID-19 first-dose vaccination coverage rates were low, particularly in high social vulnerability index (SVI) areas, but improved over time. …
Broad vaccine access should be maintained while critical outreach efforts continue to improve vaccine coverage among children aged 5–11 years, especially in high SVI areas. If COVID-19 vaccine is recommended for children aged <5 years, similar efforts to strategically maximize access and coverage might be considered.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]).
Related Link
* MMWR's main page ([link removed]) provides access to MMWR Weekly and its companion publications
------------------------------------------------------------
MMWR Recap: Articles regarding COVID-19 vaccine effectiveness and safety monitoring
CDC recently published several articles first distributed as MMWR Early Releases:
* Safety Monitoring of COVID-19 Vaccine Booster Doses among Persons Aged 12–17 Years—United States, December 9, 2021–February 20, 2022 (MMWR, March 4, HTML ([link removed]) or PDF ([link removed]) )
* Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations among Nonimmunocompromised Children and Adolescents Aged 5–17 Years—VISION Network, 10 States, April 2021–January 2022 (MMWR, March 4, HTML ([link removed]) or PDF ([link removed]) )
Related Link
* MMWR ([link removed]) main page provides access to MMWR Weekly and its companion publications
------------------------------------------------------------
Global News
------------------------------------------------------------
WHO confirms circulating vaccine-derived poliovirus in Israel
WHO published an update to their web page titled Circulating Vaccine-Derived Poliovirus Confirmed in Israel and the Occupied Palestinian Territory ([link removed]). A portion of the web page appears below.
On Monday, 7 March 2022, a case of circulating vaccine-derived poliovirus type 3 (cVDPV3) was confirmed in an unvaccinated girl aged 3 years and 9 months in Israel. The girl had developed acute flaccid paralysis and, upon testing of her stool, poliovirus was confirmed.
Further testing of the poliovirus isolated from the girl revealed genetic links to VDPV3 strains detected in environmental samples collected from sites in Israel and the occupied Palestinian territory between September 2021 and January 2022. These isolates, previously classified as ambiguous VDPV3, have now been reclassified as circulating VDPV3 (cVDPV3). This confirms an outbreak of cVDPV3 in both Israel and the occupied Palestinian territory.
------------------------------------------------------------
Upcoming Events
------------------------------------------------------------
Virtual: NFID hosts "Updates from Recent Advisory Committee on Immunization Practices (ACIP) Meetings" webinar on March 17
The National Foundation for Infectious Diseases (NFID) will offer a webinar titled Updates from Recent Advisory Committee on Immunization Practices (ACIP) Meetings ([link removed]) on March 17 at 1:00 p.m. (ET). During this program, William Schaffner, MD, NFID medical director and ACIP liaison, and Jessica MacNeil, MPH, ACIP deputy executive secretary, CDC, will discuss the latest updates including current U.S. vaccination recommendations for children, adolescents, and adults.
There is no fee to participate in this activity, but pre-registration is required ([link removed]).
------------------------------------------------------------
Virtual and In Person: Registration open for "North Dakota Immunization Conference" on June 21–22; CE available
The North Dakota Immunization Conference ([link removed]) will take place virtually and in person on June 21–22 in Bismarck, North Dakota. Conference objectives are to explore strategies and best practices to increase immunization coverage rates; evaluate communication strategies for responding to questions from patients/families; and discuss updates to the child, adolescent, and adult immunization schedule.
Continuing education credits are pending.
There is a $100 fee to attend. The fee increases to $150 after May 30.
View the schedule here ([link removed]). Register for the event ([link removed]).
------------------------------------------------------------
For more upcoming events, visit our Calendar of Events ([link removed]).
Editorial Information
Editor-in-Chief
Kelly L. Moore, MD, MPH
Managing Editor
John D. Grabenstein, RPh, PhD
Associate Editor
Sharon G. Humiston, MD, MPH
Writer/Publication Coordinator
Taryn Chapman, MS
Courtnay Londo, MA
Style and Copy Editor
Marian Deegan, JD
Web Edition Managers
Arkady Shakhnovich
Jermaine Royes
Contributing Writer
Laurel H. Wood, MPA
Technical Reviewer
Robin VanOss
About IZ Express
Immunize.org welcomes redistribution of this issue of IZ Express or selected articles. When you do so, please add a note that Immunize.org is the source of the material and provide a link to this issue ([link removed]).
IZ Express is supported in part by Grant No. 1NH23IP922654 from the National Center for Immunization and Respiratory Diseases, CDC. Its contents are solely the responsibility of Immunize.org and do not necessarily represent the official views of CDC.
IZ Express Disclaimer ([link removed])
ISSN: 2771-8085
To unsubscribe to this publication, go to: [link removed]
==============================================
Unsubscribe [email protected] from this list:
[link removed]
Message Analysis
- Sender: Immunization Action Coalition
- Political Party: n/a
- Country: United States
- State/Locality: n/a
- Office: n/a
-
Email Providers:
- MailChimp